[Show abstract] [Hide abstract]
ABSTRACT: Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2. Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2.
Bioorganic & medicinal chemistry letters 12/2009; 19(23):6529-33. DOI:10.1016/j.bmcl.2009.10.053 · 2.33 Impact Factor